Another clinical study on patients with high-risk intermediate grade B-lineage non-Hodgkin lymphoma treated either with first generation CD19-CAR-T using isolated CD8+ T CM subset or with second generation CD19-CAR-T using both CD8+ and CD4+ T CM subsets demonstrated the feasibility and safety of both approaches [35], although the group of CAR-T with CD4+ and CD8+ T CM and second generation CAR-T cells demonstrated better persistence. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.